PuSH - Publikationsserver des Helmholtz Zentrums München

Xue, B.* ; von Heyking, K.* ; Gassmann, H.* ; Poorebrahim, M.* ; Thiede, M.* ; Schober, K.* ; Mautner, J. ; Hauer, J.* ; Ruland, J.* ; Busch, D.H.* ; Thiel, U.* ; Burdach, S.E.G.*

T cells directed against the metastatic driver chondromodulin-1 in ewing sarcoma: Comparative engineering with CRISPR/Cas9 vs. retroviral gene transfer for adoptive transfer.

Cancers 14:5485 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Ewing sarcoma (EwS) is a highly malignant sarcoma of bone and soft tissue with early metastatic spread and an age peak in early puberty. The prognosis in advanced stages is still dismal, and the long-term effects of established therapies are severe. Efficacious targeted therapies are urgently needed. Our previous work has provided preliminary safety and efficacy data utilizing T cell receptor (TCR) transgenic T cells, generated by retroviral gene transfer, targeting HLA-restricted peptides on the tumor cell derived from metastatic drivers. Here, we compared T cells engineered with either CRISPR/Cas9 or retroviral gene transfer. Firstly, we confirmed the feasibility of the orthotopic replacement of the endogenous TCR by CRISPR/Cas9 with a TCR targeting our canonical metastatic driver chondromodulin-1 (CHM1). CRISPR/Cas9-engineered T cell products specifically recognized and killed HLA-A*02:01+ EwS cell lines. The efficiency of retroviral transduction was higher compared to CRISPR/Cas9 gene editing. Both engineered T cell products specifically recognized tumor cells and elicited cytotoxicity, with CRISPR/Cas9 engineered T cells providing prolonged cytotoxic activity. In conclusion, T cells engineered with CRISPR/Cas9 could be feasible for immunotherapy of EwS and may have the advantage of more prolonged cytotoxic activity, as compared to T cells engineered with retroviral gene transfer.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Chondromodulin-1 ; Crispr/cas9 ; Ewing Sarcoma ; Immunotherapy ; Orthotopic Tcr Replacement ; Retroviral Transduction
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 14, Heft: 22, Seiten: , Artikelnummer: 5485 Supplement: ,
Verlag MDPI
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
Förderungen China Scholarship Council
Deutsche Forschungsgemeinschaft
Wilhelm Sander-Stiftung
St. Baldrick's Foundation
Robert Pfleger Foundation
Hanne Sturm Memorial Foundation
Cura Placida Children’s Cancer Research Foundation
AdoRe